Jakob Knudsen
Vorstandsvorsitzender bei VIROGATES A/S
Vermögen: 142 491 $ am 31.05.2024
Profil
Jakob Knudsen is currently the Chief Executive Officer at ViroGates A, an Independent Director at ExpreS2ion Biotechnologies ApS, the Director of Mr. Knudsen Enkeltmandsvirksomhed, an Independent Director at Expres2ion Biotech Holding AB, a Director at Ingeniørsystem A, and a Non-Executive Director at P.V.
Fonden.
Previously, he held the position of Head-Business Development at ALK-Abello A from 1999 to 2008 and Chief Financial & Commercial Officer at Egalet Ltd.
from 2008 to 2011.
He holds an MBA from Imperial College London and a graduate degree from the University of Copenhagen.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VIROGATES A/S
1,95% | 31.12.2023 | 125 514 ( 1,95% ) | 142 491 $ | 31.05.2024 |
Aktive Positionen von Jakob Knudsen
| Unternehmen | Position | Beginn |
|---|---|---|
| EXPRES2ION BIOTECH HOLDING AB | Direktor/Vorstandsmitglied | 01.04.2017 |
| VIROGATES A/S | Vorstandsvorsitzender | 01.04.2011 |
ExpreS2ion Biotechnologies ApS
 ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Direktor/Vorstandsmitglied | - |
| P.V. Fonden | Direktor/Vorstandsmitglied | - |
| Ingeniørsystem A/S | Direktor/Vorstandsmitglied | - |
| Jakob Knudsen Enkeltmandsvirksomhed | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jakob Knudsen
| Unternehmen | Position | Ende |
|---|---|---|
Egalet Ltd.
 Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Finanzdirektor/CFO | 01.04.2011 |
| ALK-ABELLÓ A/S | Corporate Officer/Principal | 01.02.2008 |
Ausbildung von Jakob Knudsen
| Imperial College London | Masters Business Admin |
| University of Copenhagen | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ALK-ABELLÓ A/S | Health Technology |
| EXPRES2ION BIOTECH HOLDING AB | Health Technology |
| VIROGATES A/S | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Egalet Ltd.
Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Health Technology |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Health Technology |
| P.V. Fonden | |
| Ingeniørsystem A/S | |
| Jakob Knudsen Enkeltmandsvirksomhed |
